Daily Morning Note – 10 November 2020


European shares jumped to an eight-month high on Monday after drug makers Pfizer and BioNTech flagged strong progress in their Covid-19 vaccine, while Joe Biden’s election victory raised hopes of a more stable US trade policy. Pfizer Inc and BioNTechSE said the experimental vaccine was more than 90 percent effective in preventing Covid-19, based on initial data from a large study. The pan-European Stoxx 600 jumped nearly 4 percent and clocked its best day since late March. Travel and leisure stocks, which have been the hardest hit by the pandemic, were among the best performing sectors, adding 7 percent to hit an eight-month high.

US shares revved higher on Monday on the news a coronavirus vaccine had shown 90 percent effectiveness, but after blasting through records early in the session, Wall Street closed with more modest gains. The bellwether Dow Jones Industrial Average jumped over 830 points or 2.95 percent to finish the day at 29,157.97, while the broader S&P 500 rose 1.1 percent to 3,550.5, about 30 points shy of a record.

But the tech-heavy Nasdaq reversed early gains and slipped 0.7 percent to close at 11,713.78, as firms that benefitted from the pandemic lost ground, including Zoom and Netflix.


President Donald Trump, who is refusing to concede election defeat, injected new volatility on Monday by firing his defence secretary, while President-elect Joe Biden made good on a promise to focus on leading the country out of the Covid-19 crisis.

Vicom posted a 5 percent slip in its profit after tax and minority interest (Patmi) for the third quarter ended Sept 30, from S$7.15 million a year ago to S$6.82 million. Revenue for the vehicle-inspection firm, a subsidiary of transport operator ComfortDelGro Corp, fell by 16 percent year-on-year (y-o-y), from S$26.4 million to S$22.2 million for the quarter.

Elite Commercial Reit on Monday posted a distribution per unit (DPU) of 1.23 pence (S$0.02) for its third quarter, which is 1.7 percent higher than what it had forecast in its listing prospectus. For the three months ended Sept 30, it generated a post-tax profit of £3.3 million, a 5.6 percent drop from its forecast, on the back of a revenue of £5.8 million, which was a 0.5 percent dip from its earlier expectations.

Malaysia glove maker Riverstone Holdings on Monday announced that its net profit had grown five times to RM178.6 million (S$58.2 million) for its third quarter ended Sept 30, unhampered by rising packaging and raw material costs. Revenue rose 92 percent to RM482.3 million, due to the surge in global demand for personal protection equipment amid the Covid-19 pandemic, which led to higher average selling prices of the group’s healthcare examination gloves since June this year.

Neo Group’s first-half attributable net profit grew more than five times to S$13.6 million for the period ended Sept 30, up from S$2.3 million a year ago. This was due to higher other income contributed by higher financial grants from the government, revenue growth from its core catering and manufacturing businesses, as well as an overall reduction in operating expenses including delivery, employee benefits, and advertising.

Offshore oil and gas contractor Dyna-Mac on Monday said it has secured fabrication projects for a total provisional sum of S$157.5 million. These contracts are for the fabrication of pipe spools and construction of topside modules for floating production storage offloading vessels, it said. The projects begin in the fourth quarter of this year and are expected to be completed by the second quarter of next year.

Sunningdale Tech’s chairman Koh Boon Hwee is teaming up with Novo Tellus PE Fund 2 to make an offer for the precision plastic components manufacturer at S$1.55 in cash per share via a scheme of arrangement. This proposed acquisition was announced on Monday evening. Mr. Koh’s entity, Sunrise Technology Investment Holding II, and a subsidiary of Novo Tellus PE Fund 2 hold a 64 percent and 36 percent stake respectively in the offeror company.

Oil surged about 8 percent on Monday, its biggest daily gain in more than five months after Pfizer announced promising results for its Covid-19 vaccine. Brent crude settled at US$42.40 a barrel, up US$2.95, or 7.48 percent, while US West Texas Intermediate crude settled at US$40.29 a barrel, rising US$3.15, or 8.48 percent.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR


Olam International Ltd

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Olam International (SGX: O32) continuous downtrend has been persisting but recent technical indicate a revival of the bulls.

>> Read more Technical reports


CapitaLand Limited – Pick-up in all business segments

Recommendation: BUY (Maintained), TP: S$3.82

Last Done: S$2.64, Analyst: Natalie Ong

– Sustained recovery in all business segments in 3Q20.

– Remains committed to S$3bn divestment target and digitalisation to build stickiness and future-proof its portfolio, as well as cash conservation.

– Reiterate BUY and TP of S$3.82, at a 20% discount to RNAV. CAPL is our top pick in the sector.

>> Read more research reports

HK Reports – Read up on our Hong Kong reports here


Webinar Of The Week

Market Outlook: (PSR) StarHub, Banks & REIT Results, Banking Monthly, Credit Commentary, SG Weekly & more

Date: 09 November 2020

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #26 – iX Biopharma Ltd; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com